查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1608113

吸入藥品市場：按產品、按應用分類 - 2025-2030 年全球預測

Inhalable Drugs Market by Product (Aerosol, Dry Powder Formulation, Spray), Application (Non-Respiratory Diseases, Respiratory Diseases) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

據預測，2023年吸入藥品市值為350.1億美元，預計到2024年將達到376億美元，複合年成長率為6.05%，到2030年將達到528.4億美元。

吸入藥物是一種設計用於透過呼吸系統輸送的製劑，具有快速吸收和針對氣喘和慢性阻塞性肺病等呼吸系統疾病的針對性作用的潛在益處。對吸入藥物的需求不斷成長，是因為它們在慢性呼吸道疾病的治療中發揮著重要作用，而且此類疾病在全球範圍內的患病率不斷上升。其應用範圍廣泛，包括全身性疾病治療、疼痛管理，甚至疫苗等藥物傳遞（可透過吸入非侵入性給藥），強化了這種需求。最終用戶包括醫院、診所和家庭護理機構，反映出這些藥物的廣泛採用。市場成長受到呼吸系統疾病發病率上升、給藥系統技術進步以及對高效和患者友好的治療方案的需求等因素的顯著影響。市場區隔的機會在於新興市場的擴張、智慧吸入器等自適應技術，以及個人化醫療和生技藥品創新帶來的慢性阻塞性肺病和氣喘領域的成長。為了充分利用這一潛力，相關人員應專注於產能擴張、監管合規性以及產品開發和分銷的策略夥伴關係。儘管前景廣闊，但該市場仍面臨監管挑戰、潛在副作用和高開發成本等限制。來自口服藥物的競爭和正在進行的替代療法研究也增加了這些挑戰。需要創新的領域包括改進吸入器設計以提高劑量準確性、提高生物有效性的藥物處方以及整合數位健康技術以監測和提高患者依從性。透過了解使用者體驗並解決現有的設計缺陷，獲得對未滿足的市場需求的可行見解。總體而言，吸入藥品市場展現出動態的成長潛力，技術和創新被定位為關鍵驅動力，同時克服嚴格的監管和市場滲透挑戰對於未來的成功仍然很重要。

主要市場統計
基準年[2023] 350.1億美元
預計年份 [2024] 376億美元
預測年份 [2030] 528.4億美元
複合年成長率（%） 6.05%

市場動態：揭示快速發展的吸入藥品市場的關鍵市場洞察

供需的動態交互作用正在改變吸入藥品市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性阻塞性肺病和氣喘等呼吸系統疾病的盛行率增加
    • 增加醫療基礎設施並提高患者意識
    • 帕金森氏症等非呼吸系統疾病迅速增加
  • 市場限制因素
    • 關於吸入藥物核准的嚴格規定
  • 市場機會
    • 易於給藥的吸入藥物的快速開發
    • 活性化的運動將目前的不可吸入分子改良為可吸入分子，以改善藥物輸送。
  • 市場挑戰
    • 不受監管的替代療法的可用性

波特五力：駕馭吸入藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解吸入藥品市場的外部影響

外部宏觀環境因素在塑造吸入藥品市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解吸入藥物市場的競爭格局

對吸入藥品市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣吸入藥品市場供應商的績效評估

FPNV 定位矩陣是評估吸入藥品市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議為吸入藥物市場的成功指明了道路

對於旨在加強其在全球市場的影響力的公司來說，吸入藥品市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性阻塞性肺病和氣喘等呼吸系統疾病的發生率增加
      • 加強醫療基礎設施並意識提升
      • 帕金森氏症等非呼吸系統疾病迅速增加
    • 抑制因素
      • 吸入藥物核准的嚴格規定
    • 機會
      • 吸入藥物的快速開發以簡化給藥
      • 將目前的不可吸入分子重新配製為可吸入分子以改善藥物輸送的運動日益盛行。
    • 任務
      • 不受監管的替代療法的可用性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 吸入藥物市場：依產品

  • 氣霧劑
  • 乾粉配方
  • 噴

第7章 吸入藥物市場：依應用分類

  • 非呼吸系統疾病
  • 呼吸系統疾病

第8章美洲吸入藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太吸入藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲吸入藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
  • 戰略分析和建議

公司名單

  • Aptargroup, Inc.
  • AstraZeneca PLC
  • Avalyn Pharma, Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • GEA Group Aktiengesellschaft
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • PureIMS BV
  • Respira Therapeutics Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CA17E905E64D

The Inhalable Drugs Market was valued at USD 35.01 billion in 2023, expected to reach USD 37.60 billion in 2024, and is projected to grow at a CAGR of 6.05%, to USD 52.84 billion by 2030.

Inhalable drugs are formulations designed for delivery through the respiratory system, offering potential advantages in rapid absorption and targeted action in respiratory conditions like asthma and COPD. The growing necessity for inhalable drugs stems from their critical role in managing chronic respiratory diseases and the increasing prevalence of such conditions globally. This necessity is bolstered by their applications, which span administering medication for systemic disease treatments, pain management, and even vaccines where inhalation offers non-invasive administration. End-users include hospitals, clinics, and home care settings, reflecting the broad adoption of these drugs. Market growth is heavily influenced by factors like rising respiratory disease rates, technological advancements in drug delivery systems, and demand for efficient, patient-friendly treatment options. Opportunities lie in expanding markets in developing regions, adaptive technologies like smart inhalers, and growth in COPD and asthma segments, driven by innovation in personalized medicine and biologics. To tap into these potentials, stakeholders should focus on expanding production capabilities, regulatory compliance, and strategic partnerships for product development and distribution. Despite the promising outlook, the market faces limitations such as regulatory challenges, potential side effects; and high development costs. Competition from oral medications and ongoing research in alternative therapies add to these challenges. Areas ripe for innovation include enhancing inhaler design for better dose accuracy, formulating drugs with improved bioavailability, and integration of digital health technologies to monitor and improve patient compliance. Understanding user experiences and addressing existing design drawbacks can provide actionable insights into unmet market needs. Overall, the inhalable drugs market shows dynamic growth potential, with technology and innovation positioned as key drivers while overcoming stringent regulations and market penetration challenges remain important for future success.

KEY MARKET STATISTICS
Base Year [2023] USD 35.01 billion
Estimated Year [2024] USD 37.60 billion
Forecast Year [2030] USD 52.84 billion
CAGR (%) 6.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inhalable Drugs Market

The Inhalable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
    • Increasing healthcare infrastructure and rising awareness among patients
    • Surge in the number of non-respiratory diseases such as Parkinson's disease
  • Market Restraints
    • Strict regulations for the approval of inhalable drugs
  • Market Opportunities
    • Surge in development of inhalable drugs for ease of administration
    • Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
  • Market Challenges
    • Availability of unregulated and alternate therapy

Porter's Five Forces: A Strategic Tool for Navigating the Inhalable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inhalable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inhalable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inhalable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inhalable Drugs Market

A detailed market share analysis in the Inhalable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inhalable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inhalable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Inhalable Drugs Market

A strategic analysis of the Inhalable Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Inhalable Drugs Market, highlighting leading vendors and their innovative profiles. These include Aptargroup, Inc., AstraZeneca PLC, Avalyn Pharma, Inc., Boehringer Ingelheim International GmbH, Cipla Inc., GEA Group Aktiengesellschaft, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., PureIMS B.V., Respira Therapeutics Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Inhalable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Aerosol, Dry Powder Formulation, and Spray.
  • Based on Application, market is studied across Non-Respiratory Diseases and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
      • 5.1.1.2. Increasing healthcare infrastructure and rising awareness among patients
      • 5.1.1.3. Surge in the number of non-respiratory diseases such as Parkinson's disease
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations for the approval of inhalable drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in development of inhalable drugs for ease of administration
      • 5.1.3.2. Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of unregulated and alternate therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Inhalable Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Aerosol
  • 6.3. Dry Powder Formulation
  • 6.4. Spray

7. Inhalable Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Non-Respiratory Diseases
  • 7.3. Respiratory Diseases

8. Americas Inhalable Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Inhalable Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Inhalable Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aptargroup, Inc.
  • 2. AstraZeneca PLC
  • 3. Avalyn Pharma, Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Cipla Inc.
  • 6. GEA Group Aktiengesellschaft
  • 7. Merck & Co., Inc.
  • 8. Novartis AG
  • 9. Orion Corporation
  • 10. Pfizer Inc.
  • 11. PureIMS B.V.
  • 12. Respira Therapeutics Inc.
  • 13. Sanofi S.A.
  • 14. Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. INHALABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. INHALABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INHALABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. INHALABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. INHALABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INHALABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INHALABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INHALABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INHALABLE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INHALABLE DRUGS MARKET SIZE, BY AEROSOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INHALABLE DRUGS MARKET SIZE, BY DRY POWDER FORMULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INHALABLE DRUGS MARKET SIZE, BY SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INHALABLE DRUGS MARKET SIZE, BY NON-RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INHALABLE DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. INHALABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. INHALABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023